Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial - Xavier Mariette, Olivier Hermine, Pierre-Louis Tharaux, Matthieu Resche-Rigon, Raphael Porcher, Philippe Ravaud, Serge Bureau, Maxime Dougados, Annick Tibi, Elie Azoulay, Jacques Cadranel, Joseph Emmerich, Muriel Fartoukh, Bertrand Guidet, Marc Humbert - Dissemin

Language
Login

Published in

Elsevier, The Lancet Rheumatology, 1(4), p. e24-e32, 2022

DOI: 10.1016/s2665-9913(21)00315-5

Links

Tools

Export citation

Search in Google Scholar

Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial

Journal article published in 2021 by Xavier Mariette, Olivier Hermine, Pierre-Louis Tharaux, Matthieu Resche-Rigon, Raphael Porcher, Philippe Ravaud, Serge Bureau, Maxime Dougados, Annick Tibi, Elie Azoulay, Jacques Cadranel, Joseph Emmerich, Muriel Fartoukh, Bertrand Guidet, Marc Humbert and other authors.

This paper was not found in any repository, but could be made available legally by the author.

This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle

Preprint: archiving allowed

Upload

Green circle

Postprint: archiving allowed

Upload

Red circle

Published version: archiving forbidden

Policy details

Data provided by

SHERPA/RoMEO